NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).
“On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.”
Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
“Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.”
Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
“On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.”
Earnings Releases
NEKTAR THERAPEUTICS reported first quarter ended March 31, 2026 results: revenue 10.9 million, net income 44.9 million, EPS 1.82.
“Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.”
Material Agreements
NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately $350.9 million (effective 2026-04-21).
“On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) at a price to the public of $92.00 per Firm Share, less underwriting discounts and commissions.”
Material Agreements
NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately 432.0 million (effective 2026-02-11).
“On February 11, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”)”
“On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Reverse Stock Split Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s Common Stock at a ratio of one-for-fifteen (the “Reverse Stock Split”).”
Governance Changes
NEKTAR THERAPEUTICS: Increased authorized common shares from 300M to 390M (effective 2025-06-06).
“On June 6, 2025, Nektar Therapeutics (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Increase in Authorized Shares Amendment”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), from 300,000,000 shares to 390,000,000 shares.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.